BioLineRx/Roche Scan BL-8040-Tecentriq For Gastric Cancer
Zacks Investment Research | Oct 20, 2017 04:04AM ET
BioLineRx Ltd. (NASDAQ:BLRX) announced that its partner Genentech, a member of Roche Holding (SIX:ROG) AG (OTC:RHHBY) , has initiated a phase Ib/II study to evaluate its lead pipeline candidate, BL-8040, in combination with Roche’s Tecentriq (atezolizumab) for treating patients with gastric cancer.
Shares of BioLineRx have outperformed the industry so far this year. The stock has gained 22.3% versus the broader industry’s 1.1% increase.
The phase Ib/II multicenter, randomized, controlled, open-label combo therapy trial was designed to evaluate the safety, tolerability and multiple pharmacodynamic parameters of the combination therapy. The study will be conducted on approximately 40 patients.
In the study, patients will be administered with BL-8040 injections as priming monotherapy. Thereafter, they will receive both BL-8040 and Tecentriq injections and continue with multiple treatment cycles for up to two years or until disease progression.
We remind investors that in September 2016, BioLineRx had entered into a collaboration agreement with Genentech, to support several phase Ib studies that are investigating BioLineRx’s BL-8040 combined with Tecentriq. This is marked as the third trial to commence under BioLineRx’s collaboration with Genentech.
It’s significant to note that this joint endeavor is part of Roche’s novel cancer immunotherapy development platform MORPHEUS, a phase Ib/II adaptive platform to assess the efficacy and safety of combination cancer immunotherapies.
Significantly, BL-8040 is BioLineRx’s one of the leading therapeutic candidates, having successfully completed a phase IIa study for relapsed/refractory AML (acute myeloid leukemia) and is in the midst of a phase IIb program as an AML consolidation treatment. It is expected to initiate a phase III study on stem cell mobilization for autologous transplantation. Earlier in May, BioLineRx had announced that it has submitted a regulatory filing for commencing the phase III study.
Importantly, in July, BioLineRx had announced that Genentech has initiated another phase Ib/II trial, assessing BL-8040 in combination with Tecentriq to cure patients with metastatic pancreatic ductal adenocarcinoma.
BioLineRx had announced beginning of the first phase IIa COMBAT study for evaluating the efficacy of BL-8040 in combination with Merck's (NYSE:MRK) Keytruda on patients with pancreatic cancer, back in September 2016. Subsequently, earlier in January, BioLineRx had announced the onset of a second phase IIa study on the given combination.
Get The News You Want
BioLineRx Ltd. Price
BioLineRx Ltd. Quote
Zacks Rank & Key Picks
BioLineRx currently carries a Zacks Rank #3 (Hold). A better-ranked stock in the healthcare sector is Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) , sporting a Zacks Rank #1 (Strong Buy). You can see .
Ionis’ loss per share estimates fell from 18 cents to 17 cents for 2017 and from 35 cents to 29 cents, over the last 60 days. The company delivered positive earnings surprises in all the trailing four quarters with an average beat of 21.90%. Ionis’ shares have rallied 33.1% so far this year.
Wall Street’s Next Amazon (NASDAQ:AMZN)
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.